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Abstract 
Amyloid beta (Aβ) can aggregate and form plaques, which are considered as one of 
the major hallmarks of Alzheimer’s disease. This study aims to directly compare the 
neuroprotective activities in vitro of two marine-derived carotenoids astaxanthin and 
fucoxanthin that have shown a spectrum of biological activities, including 
neuroprotection. The in vitro neuroprotective activities were investigated against Aβ1-
42-mediated toxicity in pheochromocytoma (PC-12) neuronal cells using the MTT cell
viability assay, anti-apoptotic, antioxidant and neurite outgrowth activities; as well as 
inhibition against Aβ1-42 fibrillization in the Thioflavin T (ThT) assay of fibril kinetics 
and via transmission electron microscopic (TEM) evaluation of fibril morphology. 
The results demonstrated that both astaxanthin and fucoxanthin exhibited multi-
neuroprotective effects favouring fucoxanthin over astaxanthin supporting 
neuroprotective roles of marine-derived carotenoids as potential novel dementia 
prevention or therapeutic strategies. 
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1. Introduction
Alzheimer’s disease (AD) is a major neurodegenerative disorder responsible for more 
than 60-80% of dementia cases globally (Alzheimer'sAssociation, 2018). Aggregates 
of the protein amyloid beta (Aβ) form the amyloid plaques that are one of the main 
hallmarks of AD pathology (Hussain et al., 1999). The amyloid hypothesis suggests 
Aβ as a pathognomonic feature of AD (Hardy and Selkoe, 2002). Currently, only four 
compounds targeting acetylcholinesterase (donepezil, tacrine, rivastigmine and 
galantamine) and one drug targeting the N-methyl-D-aspartate (NMDA) receptor 
(memantine) have been approved to reduce some symptoms experienced by AD 
sufferers (Cummings et al., 2014). It was suggested that small molecules are favorable 
to target Aβ (Re et al., 2010) and could be the strategy to treat AD (Nie et al., 2011). 
Many of such molecules have demonstrated neuroprotective activities against Aβ 
cytotoxicity and aggregation such as Alzhemed, EGCG, and SEN304 (Doig and 
Derreumaux, 2015). An effective disease-modifying treatment is urgently needed, and 
drugs that target Aβ aggregation were proposed as a pathway to such treatments. Even 
though, no drug that is targeting Aβ aggregation and toxicity has been approved yet. 
The possible reason includes targeting the right target but at the wrong stage as the Aβ 
is accumulated in the body for more than 10 years before the symptoms. It will be 
difficult to treat these patients as they are in late stage (Hampel et al., 2015; Sperling 
et al., 2011). In addition, it might be insufficient to target Aβ alone to find effective 
therapeutic drug as AD is a complex disease. For that reason, drug targeting multiple 
pathways are needed in the new approach to treat AD (Piau et al., 2011).  
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Astaxanthin (Figure 1a) is a red carotenoid pigment found in different marine 
organisms such as microalgae, crustaceans, and krill (Higuera-Ciapara et al., 2006; 
Miki, 1991). It can also be found in yeasts, plants, and feathers of some birds 
(Hussein et al., 2006). Astaxanthin belongs to the xanthophyll family and is available 
commercially from microalgae Haematococcus pluvialis and yeast Phaffia rhodozyma 
(Ambati et al., 2014; Wu et al., 2015). However, it can vary in composition depending 
on the natural sources and extraction methods. Synthetic astaxanthin is a mixture of 
three isomers; (3-R,3′-R), (3-R,3′-S) and (3-S,3′-S), whereas naturally-sourced 
astaxanthin from Haematococcus pluvialis contains only the (3-S,3′-S) isomer 
(Fassett and Coombes, 2011).  
 
On the other hand, fucoxanthin (Figure 1b) is a carotenoid (also known as 
tetraterpenoid) derived from brown algae and microalgae (Peng et al., 2011). It is an 
orange coloured pigment found in high content in classes such as Phaeophyceae, 
Haptophyta, Bacillariophyceae and Chrysophyceae. It is also found in minor levels in 
Rhodophyta, Raphidophyceae, and Dinophyta (Takaichi, 2011). Fucoxanthin belongs 
to the xanthophyll class, as it contains an oxygen in the functional group which 
differentiate it from carotenes (Mikami and Hosokawa, 2013). The structure of 
fucoxanthin was illustrated for the first time in 1990 (Englert et al., 1990) and 
contains a unique allenic bond in its structure. In addition, the polyene chain contains 
an epoxide and conjugated carbonyl group (Mikami and Hosokawa, 2013).  
 
Astaxanthin has been shown to possess different biological activities, especially as an 
antioxidant. Earlier research on the antioxidant activity of astaxanthin against singlet 
oxygen species has revealed that it has over ten times the activity of other carotenoids 
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such as lutein and β-carotene, and 100 more times activity than α- tocopherol (Miki, 
1991). As for the interactions with the amyloid β protein, astaxanthin has been shown 
to protect neuronal PC-12 cells from the toxicity induced by Aβ25-35 (Chang et al., 
2010). Another study demonstrated that astaxanthin can attenuate the toxicity of Aβ25-
35 in SH-SY5Y cells through decreasing the Bcl-2/Bax ratio (Wang et al., 2010). 
Astaxanthin (at 10 µM)  exhibited stronger activity than β-carotene and canthaxanthin 
in reducing the cytotoxicity induced by Aβ25-35 (Chang et al., 2013). 
 
Fucoxanthin has shown to exhibit several bioactivities which include anti-cancer 
(Kumar et al., 2013), cardioprotective activity (Matsumoto et al., 2010), anti-obesity 
(Okada et al., 2008), anti-diabetic activity (Nishikawa et al., 2012), and antioxidant 
(Sachindra et al., 2007). Fucoxanthin was found to inhibit the neurotoxicity induced 
by Aβ1-42 in cerebral cortex neurons (Zhao et al., 2015). A recent study showed that 
fucoxanthin can inhibit the aggregation of Aβ1-42 and also was found to protect the 
SH-SY5Y cells from the neurotoxicity induced by Aβ1-42 (Xiang et al., 2017). 
Fucoxanthin was found to protect SH-SY5Y cells against Aβ oligomer via inhibiting 
ERK pathway and activating PI3K/Akt pathway (Lin et al., 2017). 
 
In all the previous studies, there was no direct comparison of these two promising 
neuroprotective carotenoids. Our aim was to undertake a systematic comparative 
study of the neuroprotective activities of both fucoxanthin and astaxanthin in a 
number of bioassays to understand their relative neuroprotective capacity. A range of 
in vitro assays were carried out to test these two compounds in a cell-based 
neuroprotective assay in reducing the toxicity of amyloid β and their anti-aggregation 
effects using the Thioflavin T (ThT) assay of fibril kinetics and transmission electron 
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microscopy (TEM) of direct fibril morphology. The antioxidant and protective effects 
against reactive oxygen species, inhibition of apoptosis induced by Aβ1-42 and 
enhancing neurite outgrowth activity were also assessed.  
2. Material and methods 
2.1 Reagents and materials 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 97.5%), 
Roswell Park Memorial Institute 1640 (RPMI), astaxanthin (SML0982) with 97% 
purity, and fucoxanthin (F6932) with 95% purity were purchased from Sigma-Aldrich 
(USA). Foetal bovine serum (FBS) was purchased from Bovogen Biologicals (East 
Keilor, VIC, Australia). Penicillin/streptomycin and 10×trypsin EDTA were obtained 
from Thermo Fisher Scientific (Scoresby, VIC, Australia). Human amyloid-β 1–42 
protein (Aβ1-42) was obtained from rPeptide (Bogart, Georgia, USA).  
2.2 PC-12 cell culture 
Rat pheochromocytoma cells PC-12 displaying a semi-differentiated phenotype 
(Ordway subclone) with neuronal projections were used and maintained in RPMI-
1640 media with 10% foetal bovine serum (FBS) and 1% (w/v) penicillin/ 
streptomycin.  
2.3 Aβ1-42 preparation and treatment in PC-12 cells 
Native, non-fibrillar Aβ1–42 was prepared by dissolving in 1% (v/v) DMSO to yield a 
protein concentration of 3.8 mM. A final concentration of 100 µM was made up by 
adding sterile PBS and was aliquoted and stored at −70 °C until required. 
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2.4 MTT assay for astaxanthin and fucoxanthin cytotoxicity, induced-
protection of cells against Aβ1-42 -induced cytotoxicity, and induced-
protection of cells  against H2O2 cytotoxicity 
The cytotoxicity of these compounds was measured using the MTT assay. Initially, 
cells were plated at 2×104 cells per well in 100 µl media and incubated at 37°C with 
5% CO2 for 24 hours. Both astaxanthin and fucoxanthin were diluted in DMSO to 
their final stock concentrations. PC-12 cells were treated with each of these 
carotenoid compounds at different concentrations (astaxanthin 0.1-50 µM; 
fucoxanthin 0.1-20 µM) and then incubated for 48 hours at 37° . The media was 
subsequently removed and replaced with 0.5 mg/mL of MTT (diluted in PBS). The 
plate was then incubated for 2 hours at 37°C. The MTT solution was then removed 
and the cells lysed with 100 µl of DMSO. The absorbance of the plate was measured 
at 570 nm with a reference wavelength of 630 nm using a microplate reader (Bio-Tek 
Instruments Inc, USA). 
 
Similarly, the procedure for cytotoxicity testing was followed as previously with some 
modifications for induced-protection of cells against Aβ1-42 -induced cytotoxicity 
procedure. After treating the cells with different concentrations of carotenoid 
compounds (astaxanthin 0.1-50 µM; fucoxanthin 0.01-2 µM), cells were incubated for 
15 minutes prior to the addition of Aβ1–42 (1 µM). Cells were then incubated for 48 
hours at 37°C prior to measurement of cell viability. 
 
For induced-protection of cells against H2O2 cytotoxicity procedure, cells were 
incubated for 15 minutes after carotenoid treatment, then treated with H2O2 (100 µM 
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and 200 µM). Cells were then incubated for 24 hours at 37°C prior to measurement of 
cell viability. 
2.5 Thioflavin T (ThT) assay of Aβ1-42 fibril and aggregate formation 
ThT (10 µM in PBS) was added with Aβ1–42 (10 µM), alone or in combination with 
three different concentrations of each of the carotenoid compounds (astaxanthin 0.1-
50 µM; fucoxanthin 0.1-10 µM). The plate was incubated at 37˚C in a fluorescence 
microplate reader (Bio-Tek, Bedfordshire, UK) with excitation at 446 nm and 
emission at 490 nm. A reading was taken every 10 minutes for 48 hours to assess 
effects on Aβ1–42 fibril kinetics. 
2.6 Transmission electron microscopy (TEM) of Aβ1-42 fibril formation 
In order to visualize the aggregation of Aβ1-42, transmission electron microscopy 
(TEM) was used to investigate the effects of the carotenoid compounds on Aβ1-42 
morphology. The samples were prepared by incubating native Aβ1–42 (10 µM) in PBS, 
alone or with astaxanthin (50 µM) or fucoxanthin (2 µM) for 48 hours at 37°C. 
Subsequently, 5 µl of each sample was placed onto a 400 mesh formvar carbon-
coated nickel electron microscopy grid (Proscitech, Kirwan, QLD, Australia) for 2 
minutes before the sample was blotted off using filter paper. After that, 10 µl of 
contrast dye containing 2% uranyl acetate was placed onto the grid, left for two 
minutes and blotted off with filter paper. Finally, the grids were loaded onto a 
specimen holder and then into a FEI Tecnai G2 Spirit Transmission Electron 
Microscope (FEI, Milton, QLD, Australia). The sample grids were then viewed using 
a magnification of 34,000–92,000× and representative images were taken. 
2.7 Nuclear staining for assessment of apoptosis  
PC-12 cells were seeded at a density of 2×104 overnight. Cells were then treated 
with astaxanthin and fucoxanthin at different concentrations for 15 minutes before 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
adding Aβ1-42 (1 µM). The cells were incubated for 48 hours and then 5 µg/mL of 
Hoechst 33258 stain was added and incubated for 10 minutes in the dark to stain the 
cell nuclei. The cells were then washed with PBS and the plates monitored using an 
EVOS FL Cell Imaging System (Thermo Fisher) fluorescence microscope. The 
percentage of apoptotic cells (n=350 cells at least per well) were calculated as 
followed: 			
	% = 			
	 ÷ 				
	(				
 +
			
) × 100 
Three independent experiments were performed for every treatment. 
2.8 Neurite outgrowth assay 
PC-12 cells were seeded at a density of 2×103 and incubated overnight at 37°C. Media 
was then replaced with serum-free media and the cells treated with astaxanthin and 
fucoxanthin samples at different concentrations for 24 hours. Cells were then 
visualized using an inverted microscope (Olympus CK2) at ×400 magnification, 
images taken from at least six random fields and then analysed using ImageJ software. 
Neurite outgrowth was considered positive when the cell projections were measured 
to be equal or longer than the size of cells, and the amount of neurite outgrowth was 
calculated from at least 200 cells per treatment. Neurite outgrowth % was calculated 
as number of cells positive for neurites (regardless of number of neurites per cell) / 
total number of cells. 
2.9 Statistical analysis 
All results were based on at least three independent experiments (n = 3). The effects 
of carotenoid compounds on PC-12 cell viability were analysed using one-way 
ANOVA followed by Tukey’s honestly significant difference (HSD) post-hoc test 
using SPSS software (Version 22). Area under the curve (AUC) analysis was 
measured by comparing the different treatments against Aβ1-42 using one-way 
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ANOVA with Tukeys HSD post-hoc test. Differences were considered statistically 
significant at p <0.05. 
3. Results and Discussion 
  
3.1 Cytotoxicity of astaxanthin and fucoxanthin and protection against Aβ1-42 
-induced cytotoxicity 
Astaxanthin did not show any cytotoxicity when it was incubated with PC-12 cells, 
even at the highest concentration (50 µM) tested (Figure 2a). It was reported that 
astaxanthin is very safe for  human consumption (Guerin et al., 2003) and was 
approved  to be used as a food supplement by United States Food and Drug 
Administration (Guerin et al., 2003; Stewart et al., 2008).  
 
Fucoxanthin showed a significant reduction in PC-12 cell viability at ≥5 µM and has 
negligible toxicity below 2 µM (Figure 2b). This is similar to a previous study in 
which fucoxanthin was toxic at 10 µM in human lymphocytes for 24 hours, reducing 
cell viability to 40% (Molina et al., 2014). Fucoxanthin was also toxic to HaCaT cells 
(keratinocytes) at 40 µM or more when treated for 16 hours (Zheng et al., 2013). As 
both the incubation times and cell lines are different, this may explain the variation in 
toxic concentrations. By contrast, fucoxanthin did not show any sign of toxicity in 
ICR mice administrated 1000 mg/kg and 2000 mg/kg doses (Beppu et al., 2009). 
Fucoxanthin did not show any toxicity to HUVEC cells or zebrafish and was 
protective against high glucose-induced intracellular reactive oxygen species (ROS) at 
50 µM (Kang et al., 2014). Using weanling female Wistar rats, fucoxanthin did not 
show any toxicity up to 100 mg/kg dosage(Ravi et al., 2015). It is likely that some cell 
lines are more sensitive than others, such as the PC-12 cells in the current study. 
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Treating PC-12 cells with Aβ1-42 (1 µM) resulted in cell viability decreasing to 71%, 
with astaxanthin pre-treatment providing significant neuroprotection against Aβ1-42 at 
all tested concentrations (p<0.05, Figure 2a). This protective activity was even 
significant at the lowest concentration used (0.1 µM; p<0.05). This result is consistent 
with earlier studies reporting that astaxanthin at 0.1 µM can reduce the toxicity of 
Aβ25-35 in PC-12 cells when treated for 48 hours (Chang et al., 2010), and that treating 
SH-SY5Y cells with astaxanthin at 10 µM for 24 hours can rescue cell viability lost to 
Aβ25-35 (Wang et al., 2010).  
 
Treating PC-12 cells with fucoxanthin ˂ 2µM significantly reduced the cytotoxicity of 
Aβ1-42 in a concentration-dependent manner (Figure 2b). In fact, fucoxanthin showed 
significant neuroprotection to PC-12 cells against Aβ1-42 at all tested concentrations 
(0.01–2 µM) in this study (p<0.05). These results are comparable to recent studies as 
1 µM of fucoxanthin demonstrated the ability to increase cell viability compromised 
by Aβ1-42 in SH-SY5Y cells from 50% to almost 80% (Xiang et al., 2017), and  
increase cell viability from 55% to 87% comparing to control Aβ oligomer-induced 
toxicity in SH-SY5Y cells (Lin et al., 2017).  In our study 1 µM of fucoxanthin was 
able to increase cell viability compromised by Aβ1-42 from around 67% to 98.5% in 
PC12 cells. A recent study on the neuroprotective activity of fucoxanthin showed that 
it was able to protect cerebral cortical neurons against the toxicity induced by Aβ25-35 
(Zhao et al., 2015). In addition, fucoxanthin inhibited BACE1 with an IC50 of 5.31 
µM (Jung et al., 2016). Earlier studies and the current results together suggest that 
both carotenoid compounds are neuroprotective to cell lines against the cytotoxicity 
induced by Aβ
 
(all forms). 
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3.2 Effects of astaxanthin and fucoxanthin on Aβ1-42 fibril and aggregate 
formation 
The ThT assay was used to study the kinetics of any anti-aggregative effect of 
astaxanthin and fucoxanthin against Aβ. The ThT assay demonstrated that Aβ1-42 
formed fibrils, as the fluorescence increased substantially over 48 hours, while 
astaxanthin inhibited Aβ1-42 fibril formation in a concentration-dependent manner over 
this period (Figure 3a). Area under the curve analysis showed that 1 µM astaxanthin 
was able to reduce Aβ1-42 aggregation by 50% (Figure 3b). Astaxanthin at 50 µM 
showed the highest anti-aggregation activity, with almost 80% reduction in the 
intensity of ThT fluorescence.  
Similarly, fucoxanthin inhibits Aβ1-42 fibril formation in a concentration-dependent 
manner. However, 1-10 µM fucoxanthin inhibited fibril formation dramatically 
(Figure 3c). Fucoxanthin at 2 µM was able to reduce the aggregation of Aβ1-42 by 75% 
(Figure 3d). The strongest activity was at 10 µM, but this concentration was toxic to 
PC-12 cells.  Earlier research demonstrated that fucoxanthin at more than 1 µM was 
able to reduce 50% of Aβ1-42 aggregation (Xiang et al., 2017), while in this study 1 
µM of fucoxanthin was able to reduce more than 50% of Aβ1-42 aggregation.   
To our knowledge, this evidence collectively is the first report of anti-aggregation 
effects of astaxanthin against Aβ1-42. 
3.3 Effects of astaxanthin and fucoxanthin on Aβ1-42 fibril and aggregate 
morphology 
Examining the morphology of Aβ1-42 aggregates using transmission electron 
microscopy (TEM) showed that Aβ1-42 formed fibrils and aggregates after 48 hours 
incubation (Figure 4a). In the presence of astaxanthin (50 µM), fibrils were observed 
to be similar in morphology but less prevalent than control Aβ1-42 sample (Figure 4b).  
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TEM analysis showed that fucoxanthin inhibited the formation of fibrils and truncated 
fibril length (Figure 4c). The ThT assay results were confirmed by the electron 
micrographs for fucoxanthin, where it inhibited aggregation of Aβ1-42. This finding 
supports  a previous study showing that fucoxanthin was able to inhibit the 
aggregation of Aβ1-42 while  concomitantly alleviating cognitive impariment in an 
animal model (Xiang et al., 2017). 
3.4 Astaxanthin and fucoxanthin inhibited Aβ1-42-induced apoptosis 
Treating PC-12 cells with Aβ1-42 (1 µM) for 48 hours and measuring apoptosis using 
the Hoechst 33258 nuclear stain resulted in approximately 20% of apoptotic cells 
(Figure 5). However, cells treated with astaxanthin or fucoxanthin at different 
concentrations resulted in a reduction in the number of apoptotic cells in a 
concentration-dependent manner. Lin et al. demonstrated that Aβ oligomer induced 
about 60% of apoptosis cells in SH-SY5Y cells, and  treating the cells with 3 µM 
fucoxanthin reduced apoptotic cells to 20% (Lin et al., 2017). This result is consistent 
with a report that astaxanthin inhibited apoptosis induced by H2O2 in mouse neural 
progenitor cells (Kim et al., 2009), 6-OHDA in SH-SY5Y cells (Ikeda et al., 2008) 
and Aβ25-35 in SH-SY5Y cells (Wang et al., 2010). Similarly, fucoxanthin  has been 
previously shown to reduce apoptosis induced by both H2O2 (Yu et al., 2017) and Aβ 
oligomer in SH-SY5Y cells (Lin et al., 2017). These results suggested that both 
compounds demonstrate a pleitropic neuroprotective effect in vitro, by inhibiting 
overt toxicity, apoptosis and aggregation of Aβ1-42. 
3.5 Protection of PC-12 cells against H2O2-induced cytotoxicity 
Cell viability was significantly decreased after treating PC-12 cells with 100-200 µM 
hydrogen peroxide (H2O2) (Figures 6a- 6d). At 100 µM H2O2, cell viability was 
reduced to 60%, while at 200 µM H2O2 cell viability was only 30% (Figure 6a - 6b). 
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Astaxanthin provided significant neuroprotection to PC-12 cells against H2O2-induced 
cytotoxicity, with cell viability exceeding 65% (p<0.05, Figure 6a), and 36% (p<0.05, 
Figure 6b) at both H2O2 concentrations, respectively. Astaxanthin is a known 
antioxidant, reportedly 10 times stronger than other carotenoids and 100 times 
stronger than α-tocopherol (Miki, 1991).  In addition, astaxanthin has been shown 
previously to protect differentiated PC-12 cells from H2O2-induced cytotoxicity (Chan 
et al., 2009). Our results also demonstrated that astaxanthin was an effective 
antioxidant, reducing the cytotoxicity induced by H2O2 in PC-12 cells significantly 
and at low concentrations. 
 
While fucoxanthin did not show significant protection against H2O2 to PC-12 cells at 
the lowest concentrations tested (0.01–0.1 µM), it demonstrated significant protection 
at higher concentrations (0.5–2 µM; Figure 6c (p<0.05)). Fucoxanthin at the highest 
concentration (2 µM) demonstrated a significant increase in cell viability against 
H2O2 at 200 µM (Figure 6d). These results are supported by an earlier study when 
fucoxanthin was found to inhibit the cytotoxicity of H2O2 in SH-Sy5Y cells (Yu et al., 
2017). However, this study demonstrated lower protection as the other study showed 
increase in cell viability from 50% to 79% and 98% when treated at 1 and 3 µM 
fucoxanthin, respectively. These differences might account for different cell lines 
used. Fucoxanthin was reported to have strong antioxidant activity by inhibiting 
DPPH (2,2-diphenyl-1-picrylhydrazyl) formation with an IC50 of 164.60 µM and 
showed 13.5 times higher activity than previously reported for α-tocopherol in 
hydroxyl radical-scavenging assay (Sachindra et al., 2007). Additionally, a previous 
study found that fucoxanthin could reduce the toxicity induced by H2O2 in Vero cells 
in a concentration-dependent manner (5-200 µM) (Heo et al., 2008). Recently, 
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fucoxanthin was found to inhibit cytotoxicity induced by H2O2 in SH-SY5Y cells and 
to activate the PI3K/Akt cascade and inhibit the ERK pathway (Yu et al., 2017). Our 
study found that fucoxanthin at 0.1 - 4 µM was able to increase PC-12 cell viability 
against H2O2 at 100 µM. However, fucoxanthin at 2 µM was only able to significantly 
reduce cytotoxicity induced by 200 µM H2O2.  
 
It is clear from our results that astaxanthin was more effective than fucoxanthin in 
reducing the cytotoxicity induced by hydrogen peroxide.  
3.6 Astaxanthin and fucoxanthin can enhance neurite outgrowth activity 
Enhancing neurite outgrowth is considered as one strategy to treat neurodegenerative 
diseases, as it can help maintain neuronal plasticity and communication (Koliatsos et 
al., 1991). It was found that decreasing the level of nerve growth factor (NGF) can 
result in neuronal dysfunction (Hefti and Weiner, 1986), while NGF can increase 
neuronal survival (Kromer, 1987). Also, NGF was found to enhance neurite 
outgrowth (Huang and Reichardt, 2001).  
 
In this study, astaxanthin and fucoxanthin enhanced neurite outgrowth activity in PC-
12 cells (Figure 7). Around 8% of cells developed neurites in the control group over 
24 hours, while treatment with astaxanthin and fucoxanthin increased the number of 
neurites in a concentration-dependent manner. Astaxanthin was able to promote 13.6 - 
23.7% of cells to develop neurite outgrowth at concentrations ranging from 0.1 to 50 
µM.  
On the other hand, fucoxanthin demonstrated more potent neurite outgrowth activity, 
as it was able to promote 15.7 - 31% of cells to develop neurite outgrowth in a 
concentration dependent manner at much lower concentrations (0.1 to 2 µM). This is 
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the first report of these compounds possessing such activity, which further highlights 
the potential neuroprotective activities of these compounds. Previously, a methanolic 
extract of Sargassum macrocarpum (brown algae) and a PBS extract from Jania 
adharens (red algae) elicited neurite outgrowth activity in PC-12 cells (Kamei and 
Sagara, 2002). Five compounds (MC14, sargaquinoic acid, sargachromenol, 
pheophytin A, and fucoidan) from algae were also shown to be able to enhance 
neurite outgrowth activity from previous studies (Alghazwi et al., 2016).  
 
Astaxanthin may work through inhibiting apoptosis via caspase 3, the expression of 
Bax and ROS (Chang et al., 2010; Zhang et al., 2015), the latter further supported 
through known antioxidant activity of fucoxanthin (Zhao et al., 2015). Fucoxanthin 
was also previously investigated for its activity against beta-site amyloid precursor 
protein cleaving enzyme 1 (BACE1) (Jung et al., 2016). Molecular docking studies 
revealed that two hydroxyl groups of fucoxanthin interact with two residues of the 
BACE1 enzyme (Gly11 and Ala127) (Jung et al., 2016), thereby raising the 
possibility that it may also inhibit Aβ production. Our study suggests that fucoxanthin 
is able to decrease the fibrillization and cytotoxicity of Aβ1-42, inferring that 
fucoxanthin may have multiple targets for inhibiting Aβ toxicity in Alzheimer’s 
disease.  
 
In a review on neuroprotective compounds derived from macroalgae, fucoxanthin was 
considered to be a promising compound due to its multiple neuroprotective pathways 
(Alghazwi et al., 2016), while astaxanthin has also been considered to be a promising 
compound for the treatment of neurological diseases (Wu et al., 2015). Our work 
supports their neuroprotective activities, as both compounds reduced the toxicity of 
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Aβ1-42 and H2O2. Moreover, this study showed an anti-aggregation effect against 
fibrils formed by Aβ1-42.. In addition, both astaxanthin and fucoxanthin were shown to 
inhibit apoptosis induced by Aβ1-42 and promote neurite outgrowth. As fucoxanthin 
demonstrated higher neuroprotective activity than astaxanthin at much lower 
concentration, more focus on fucoxanthin in the prevention and treatment of 
neurodegenerative diseases is recommended, but with consideration of its potential 
neurotoxicity at higher concentrations. Astaxanthin may be considered as a 
complementary treatment, possibly within nutraceutical applications. 
 
Astaxanthin has low bioavailability, but the presence of fat can increase the 
bioavailability of astaxanthin. An example is that polysorbate 80 can enhance the 
bioavailability of astaxanthin by almost 4-fold (Odeberg et al., 2003). Astaxanthin 
showed the highest bioavailability than other carotenoids (β-carotene and lutein) (Rao 
et al., 2013). Similarly, the bioavailability of fucoxanthin can be increased using 
different agents such as carrier oils and skimmed milk (Mok et al., 2018; Salvia-
Trujillo et al., 2015).  Further studies on the bioavailability and pharmacokinetics will 
be required for practical applications of these compounds. 
 
Even though some of the neuroprotective activities have been reported before in 
various biological models for astaxanthin and fucoxanthin, this is the first study that 
used a range of neuroprotective assays to compare different neuroprotective activities 
in one model. The current study unambiguously demonstrated that both astaxanthin 
and fucoxanthin possess multiple neuroprotective activities but with different potency 
in a range of bioassays testing different protection mechanisms. At 10-fold less 
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concentration, fucoxanthin demonstrated both higher neuroprotective and neurite-
promoting activity against Aβ1-42 than astaxanthin.  
4. Conclusion 
This study contributes to advance our knowledge in systematic understanding of 
neuroprotective activities and relative potencies of astaxanthin and fucoxanthin for its 
future development. Both astaxanthin and fucoxanthin exhibited neuroprotective 
activities by reducing Aβ1-42 toxicity and hydrogen peroxide in PC-12 cells. In 
addition, these two compounds inhibited the aggregation of Aβ1-42. Fucoxanthin 
showed higher neuroprotective activity against Aβ1-42 than astaxanthin. Astaxanthin 
and fucoxanthin are promising neuroprotective marine-derived compounds, and 
further research on pharmacokinetics and clinical trials would be required for the 
development as food supplements or drugs for treating neurodegenerative diseases 
such as Alzheimer’s disease.  
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Figure 1: The chemical structure of astaxanthin (a) and fucoxanthin (b) 
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Figure 2: Cell viability (%) of PC12 cells measured by MTT assay following 48 h 
treatment with astaxanthin (a) or fucoxanthin (b), and neuroprotection activity of 
astaxanthin and fucoxanthin against Aβ1-42 (1 µM) induced cytotoxicity. Each value is 
the mean ± SEM of four independent experiments (#p <0.005 vs PBS, *p <0.05, **p 
<0.01, and ***p <0.005 vs control 1 µM Aβ1-42) 
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Figure 3: Thioflavin T (ThT) fluorescence assay demonstrating amyloid Aβ1–42 
fibrillization kinetics over 48 h in PBS, alone or in the presence of different 
concentrations of astaxanthin (0.1–50 µM) (a) or fucoxanthin (0.1–10 µM) (c). Area 
under the curve (AUC) was measured to quantitate the summative effect of 
astaxanthin (b) or fucoxanthin (d) on Aβ1-42 kinetics (*p <0.05, **p <0.01, and ***p 
<0.005 vs control Aβ1-42) of astaxanthin or fucoxanthin at different concentrations 
(n=4) 
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Figure 4: Representative TEM micrographs of Aβ1–42 fibrils, alone and following 48 h 
incubation with astaxanthin or fucoxanthin: (a) Aβ1–42; (b) Aβ1–42 and astaxanthin (50 
µM) and (c) Aβ1–42 and fucoxanthin (2 µM). Scale bar: 500 nm. 
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Media 
 
Aβ1-42 (1µM) 
 
Aβ1-42 (1µM) + astaxanthin at 0.1 µM 
 
Aβ1-42 (1µM) + astaxanthin at 50 µM 
 
Aβ1-42 (1µM) + fucoxanthin at 0.01 µM 
 
Aβ1-42 (1µM) + fucoxanthin at 2 µM 
 
Figure 5: Effect of different concentrations of astaxanthin and fucoxanthin on 
apoptosis induced by Aβ1-42   in PC12 cells over 48 hours. Cells were stained using 
Hoechst 33258 and then visualized using fluorescence microscopy. At least 350 cells 
were counted for every treatment. Each value is the mean ± SEM of four independent 
experiments (#p <0.005 versus PBS, *p <0.05 and ***p <0.005 versus control Aβ1-
42).  
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Figure 6: Effect of different concentrations of astaxanthin (a, b) and fucoxanthin (c, 
d) on viability of PC12 cells exposed to H2O2 at 100 µM (a, c) and 200 µM (b, d) for 
24 h. Each value is the mean ± SEM of four independent experiments (#p <0.005 
versus PBS, *p <0.05 and ***p <0.005 versus control H2O2) 
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Figure 7: Effect of different concentrations of astaxanthin and fucoxanthin on 
enhancing neurite outgrowth in PC12 cells. Cells were visualized using light 
microscopy. At least 200 cells were counted for every treatment. Each value is the 
mean ± SEM of six independent experiments (*p <0.05 and ***p <0.005 versus 
control media) 
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- Astaxanthin and fucoxanthin provided neuroprotection against Aβ1-42 
- Both compounds showed anti-aggregation effects against Aβ1-42 
- Both compounds demonstrated multiple neuroprotective activities 
- Fucoxanthin showed higher anti-aggregation and neurite outgrowth activity 
